Stock analysts at TD Cowen started coverage on shares of Simulations Plus (NASDAQ:SLP – Get Free Report) in a report issued on Tuesday, Marketbeat.com reports. The firm set a “hold” rating and a $16.00 price target on the technology company’s stock. TD Cowen’s target price would indicate a potential upside of 3.36% from the stock’s current price.
A number of other analysts have also issued reports on SLP. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research report on Tuesday, July 15th. Cowen started coverage on Simulations Plus in a report on Tuesday. They set a “hold” rating on the stock. JMP Securities reiterated a “market perform” rating on shares of Simulations Plus in a research note on Wednesday, June 18th. Craig Hallum decreased their price target on shares of Simulations Plus from $45.00 to $36.00 and set a “buy” rating for the company in a research report on Friday, June 13th. Finally, BTIG Research cut their price target on shares of Simulations Plus from $41.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, July 7th. Four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $24.40.
Get Simulations Plus alerts:
Read Our Latest Report on SLP
Simulations Plus Trading Up 2.7%
NASDAQ SLP opened at $15.48 on Tuesday. The stock has a market cap of $311.61 million, a P/E ratio of -4.91 and a beta of 0.99. The company’s fifty day simple moving average is $14.23 and its 200-day simple moving average is $21.56. Simulations Plus has a 52 week low of $12.39 and a 52 week high of $37.67.
Simulations Plus (NASDAQ:SLP – Get Free Report) last released its quarterly earnings results on Monday, July 14th. The technology company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.19. Simulations Plus had a negative net margin of 78.63% and a positive return on equity of 11.62%. The business had revenue of $20.36 million during the quarter, compared to analyst estimates of $22.83 million. During the same period last year, the business earned $0.27 EPS. The business’s revenue was up 9.8% on a year-over-year basis. On average, research analysts expect that Simulations Plus will post 1.09 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC increased its position in Simulations Plus by 200.7% in the fourth quarter. Millennium Management LLC now owns 44,841 shares of the technology company’s stock worth $1,251,000 after buying an additional 29,929 shares during the period. Public Employees Retirement System of Ohio grew its position in shares of Simulations Plus by 58.6% during the fourth quarter. Public Employees Retirement System of Ohio now owns 41,692 shares of the technology company’s stock worth $1,163,000 after acquiring an additional 15,399 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Simulations Plus by 20,727.1% in the 1st quarter. GAMMA Investing LLC now owns 17,703 shares of the technology company’s stock worth $434,000 after acquiring an additional 17,618 shares during the period. Rhumbline Advisers lifted its position in Simulations Plus by 2.1% in the 1st quarter. Rhumbline Advisers now owns 66,222 shares of the technology company’s stock valued at $1,624,000 after purchasing an additional 1,334 shares during the last quarter. Finally, Fifth Third Bancorp boosted its stake in Simulations Plus by 33.8% during the 1st quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company’s stock valued at $36,000 after purchasing an additional 375 shares during the period. Institutional investors and hedge funds own 78.08% of the company’s stock.
Simulations Plus Company Profile
(Get Free Report)
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Featured Stories
Five stocks we like better than Simulations Plus
3 REITs to Buy and Hold for the Long Term
Datavault AI: The New AI Contender Backed by Big Funding
What is Forex and How Does it Work?
CoreWeave: Why the New King of AI Infrastructure Has Room to Run
How to Know if a Stock Pays Dividends and When They Are Paid Out
Top 3 Dividend Achievers for October: High Yields, Growth Ahead